SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

YIELD10 Bioscience, Inc. – ‘10-Q’ for 9/30/22 – ‘R15’

On:  Monday, 11/14/22, at 4:14pm ET   ·   For:  9/30/22   ·   Accession #:  1121702-22-49   ·   File #:  1-33133

Previous ‘10-Q’:  ‘10-Q’ on 8/10/22 for 6/30/22   ·   Next:  ‘10-Q’ on 5/12/23 for 3/31/23   ·   Latest:  ‘10-Q’ on 5/15/24 for 3/31/24   ·   3 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

11/14/22  YIELD10 Bioscience, Inc.          10-Q        9/30/22   60:4.8M

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.02M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     21K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     21K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
10: R1          Cover                                               HTML     69K 
11: R2          Condensed Consolidated Statements of Operations     HTML     85K 
                Unaudited                                                        
12: R3          Condensed Consolidated Balance Sheets Unaudited     HTML    112K 
13: R4          Condensed Consolidated Balance Sheets               HTML     35K 
                (Parenthetical)                                                  
14: R5          Condensed Consolidated Statements of Comprehensive  HTML     44K 
                Loss Unaudited                                                   
15: R6          Condensed Consolidated Statements of Cash Flows     HTML     89K 
                Unaudited                                                        
16: R7          Condensed Consolidated Statements of Stockholders'  HTML     81K 
                Equity                                                           
17: R8          Accounting Policies                                 HTML     51K 
18: R9          Nature of Business and Basis of Presentation        HTML     32K 
19: R10         Basic and Diluted Net Loss Per Share                HTML     28K 
20: R11         Investments                                         HTML     37K 
21: R12         Fair Value Measurements                             HTML     50K 
22: R13         Accrued Expenses                                    HTML     27K 
23: R14         Stock-Based Compensation                            HTML     37K 
24: R15         Leases                                              HTML     46K 
25: R16         Commitments and Contingencies                       HTML     27K 
26: R17         License Agreements                                  HTML     21K 
27: R18         Geographic Information                              HTML     42K 
28: R19         Capital Stock and Warrants                          HTML     42K 
29: R20         Accounting Policies (Policies)                      HTML     93K 
30: R21         Accounting Policies (Tables)                        HTML     37K 
31: R22         Basic and Diluted Net Loss Per Share (Tables)       HTML     26K 
32: R23         Investments (Tables)                                HTML     36K 
33: R24         Fair Value Measurements (Tables)                    HTML     47K 
34: R25         Accrued Expenses (Tables)                           HTML     26K 
35: R26         Stock-Based Compensation (Tables)                   HTML     35K 
36: R27         Leases (Tables)                                     HTML     44K 
37: R28         Geographic Information (Tables)                     HTML     39K 
38: R29         Capital Stock and Warrants (Tables)                 HTML     43K 
39: R30         ACCOUNTING POLICIES - Additional Information        HTML     35K 
                (Details)                                                        
40: R31         ACCOUNTING POLICIES - Schedule of Cash And          HTML     27K 
                Restricted Cash (Details)                                        
41: R32         Nature of Business and Basis of Presentation        HTML     20K 
                (Details)                                                        
42: R33         Basic and Diluted Net Loss Per Share (Details)      HTML     27K 
43: R34         Investments (Details)                               HTML     30K 
44: R35         FAIR VALUE MEASUREMENTS - Assets and Liabilities    HTML     45K 
                Measured at Fair Value on a Recurring Basis                      
                (Details)                                                        
45: R36         Accrued Expenses (Details)                          HTML     29K 
46: R37         Stock-Based Compensation (Details)                  HTML     82K 
47: R38         Stock-Based Compensation - RSU Activity (Details)   HTML     28K 
48: R39         LEASES - Narrative (Details)                        HTML     31K 
49: R40         LEASES - Maturity Analysis of Lease Liabilities     HTML     38K 
                (Details)                                                        
50: R41         LEASES - Quantitative Disclosure of Lease Costs     HTML     33K 
                (Details)                                                        
51: R42         Commitments and Contingencies (Details)             HTML     32K 
52: R43         Geographic Information (Details)                    HTML     31K 
53: R44         CAPITAL STOCK AND WARRANTS - Narrative (Details)    HTML     39K 
54: R45         CAPITAL STOCK AND WARRANTS - Schedule Of Warrants   HTML     34K 
                Issuance (Details)                                               
55: R46         CAPITAL STOCK AND WARRANTS - Schedule of Common     HTML     25K 
                Stock Reserved For Future Issuance (Details)                     
58: XML         IDEA XML File -- Filing Summary                      XML    103K 
56: XML         XBRL Instance -- yten-20220930_htm                   XML   1.11M 
57: EXCEL       IDEA Workbook of Financial Reports                  XLSX    100K 
 6: EX-101.CAL  XBRL Calculations -- yten-20220930_cal               XML    135K 
 7: EX-101.DEF  XBRL Definitions -- yten-20220930_def                XML    311K 
 8: EX-101.LAB  XBRL Labels -- yten-20220930_lab                     XML   1.05M 
 9: EX-101.PRE  XBRL Presentations -- yten-20220930_pre              XML    584K 
 5: EX-101.SCH  XBRL Schema -- yten-20220930                         XSD     96K 
59: JSON        XBRL Instance as JSON Data -- MetaLinks              296±   448K 
60: ZIP         XBRL Zipped Folder -- 0001121702-22-000049-xbrl      Zip    259K

‘R15’   —   Leases

This is an IDEA Financial Report.  [ Alternative Formats ]

 
 <>  v3.22.2.2
LEASES
 9 Months Ended
Leases [Abstract]  
LEASES LEASES
Maturity Analysis of Lease Liabilities
The Company's Woburn, Massachusetts facility is the only lease included in the Company's right-of-use assets and corresponding lease liabilities. No other active real estate or equipment leases fall within the scope of ASC 842. At September 30, 2022, the Company's lease liability related to its Woburn facility will mature as follows:
Year ended December 31,Undiscounted Cash Flows
2022 (October to December)$183 
2023749 
2024771 
2025793 
2026747 
Total undiscounted future lease payments3,243 
Amount of lease payments representing interest(460)
Total lease liabilities$2,783 
     Short-term lease liability$559 
     Long-term lease liability$2,224 
Quantitative Disclosure of Lease Costs
Three Months Ended
   September 30,		Nine Months Ended
  September 30,
2022202120222021
Lease cost:
Operating lease cost$151 $151 $454 $454 
Short-term lease cost177 171 509 497 
Sublease income(155)(148)(450)(468)
Total lease cost, net$173 $174 $513 $483 
Other information as of:September 30, 2022December 31, 2021
Weighted-average remaining lease term (years)4.24.9
Weighted-average discount rate7.25%7.25%
Real Estate Leases
    During 2016, the Company entered into a lease agreement, as amended, for its headquarters pursuant to which the Company leases 22,213 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease agreement will terminate on November 30, 2026 and does not include options for an early termination or for an extension of the lease. Pursuant to the lease, the Company is required to pay certain pro rata taxes and
operating costs associated with the premises throughout the term of the lease. During the initial buildout of the rented space, the landlord paid for certain tenant improvements that resulted in increased rental payments by the Company. As required by ASC 842, these improvements were recorded as a reduction in the valuation of the associated right-of-use asset. The Company has provided the landlord with a security deposit of $229.
In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of approximately 9,874 square feet of its leased facility located in Woburn, Massachusetts. The CJ sublease is coterminous with the Company's master lease and CJ will pay rent and operating expenses proportionate to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease. Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $3,243 shown in the lease maturity analysis table above. CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.
The Company's wholly-owned subsidiary, YOI, located in Saskatoon, Saskatchewan, Canada, leases approximately 8,600 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place. None of the leases contain renewal or early termination options. YOI's leases for these facilities expire on various dates through May 2023.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
11/30/26
Filed on:11/14/228-K
For Period end:9/30/224
12/31/2110-K,  4
 List all Filings 

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/24/23  YIELD10 Bioscience, Inc.          424B5                  1:587K

2 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/11/22  YIELD10 Bioscience, Inc.          10-Q        3/31/22   59:4.5M
 3/25/22  YIELD10 Bioscience, Inc.          10-K       12/31/21   83:9.4M
↑Top
Filing Submission 0001121702-22-000049   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Fri., May 17, 8:36:33.1am ET